• Strong top-line growth, underlying profitability and cash generation
• Four assets in pivotal / Phase 3 trials
• Advancing five high-value clinical programs

Telix Pharmaceuticals Ltd delivered strong financial results for FY 2025, with revenue growth of 56% year-over-year to $804M, meeting increased guidance. Precision Medicine revenue grew 22% to $622M, driven by strong commercial execution. The company maintained a disciplined approach to investment and cost control while positioning for growth, with Group EBITDA of $40M and a positive cash balance of $142M. Telix has four assets in pivotal/Phase 3 trials and is advancing five high-value clinical programs, including in prostate cancer, glioblastoma, clear cell renal cell carcinoma, and metastatic bone pain. The company plans to maintain R&D investment in the mid-20% range of revenue, with a focus on advancing the therapeutics pipeline. Telix also expanded its manufacturing and supply chain capabilities through strategic investments, including the acquisition of RLS Radiopharmacies. The company provided FY 2026 revenue guidance of $950M to $970M, based on approved products and geographies, and R&D guidance of $200M to $240M.

FY 2026 revenue guidance of $950M to $970M, based on approved products and geographies. R&D guidance of $200M to $240M.

Telix will continue to reinvest its earnings to position the company for long-term growth, with a focus on advancing its therapeutics pipeline and expanding its commercial capabilities globally.